Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design

被引：0
|
作者：
Miki Imazu
Atsushi Nakano
Shin Ito
Toshimitsu Hamasaki
Masafumi Kitakaze
机构：
[1] National Cerebral and Cardiovascular Center,Department of Clinical Medicine and Development
[2] GlaxoSmithKline K.K,Department of Medical Affairs Division
[3] National Cerebral and Cardiovascular Center,Department of Data Science
来源：
Cardiovascular Drugs and Therapy | 2019年 / 33卷
关键词：
Left ventricular diastolic dysfunction; Type 2 diabetes mellitus; DPP-IV inhibitors; Teneligliptin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：363 / 370
页数：7
相关论文
共 50 条
  • [1] Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design
    Imazu, Miki
    Nakano, Atsushi
    Ito, Shin
    Hamasaki, Toshimitsu
    Kitakaze, Masafumi
    CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (03) : 363 - 370
  • [2] DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial
    Yoshihara, Fumiki
    Imazu, Miki
    Sakuma, Ichiro
    Hiroi, Yukio
    Hara, Hisao
    Okazaki, Osamu
    Ishiguro, Chizuru
    Izumi, Chisato
    Noguchi, Teruo
    Shiraiwa, Toshihiko
    Nishioka, Norio
    Fujii, Kenshi
    Iwakura, Katsuomi
    Tomonaga, Osamu
    Kobayashi, Koichi
    Himi, Toshiharu
    Takihata, Masahiro
    Yumoto, Kazuhiko
    Takase, Hiroyuki
    Shimizu, Ikki
    Murakami, Tsutomu
    Wagatsuma, Kenji
    Sato, Katsuhiko
    Hiramatsu, Takeyuki
    Akabame, Satoshi
    Hata, Shiro
    Asakura, Masanori
    Kawabata, Takanori
    Omae, Katsuhiro
    Ito, Shin
    Kitakaze, Masafumi
    ECLINICALMEDICINE, 2023, 66
  • [3] Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial
    Yang, Xue
    He, Zhiwei
    Yuan, Li
    Huang, Wenbin
    Li, Doudou
    Xiang, Pingping
    Chen, Yu
    Chen, Guofang
    Liu, Chao
    BMC ENDOCRINE DISORDERS, 2023, 23 (01)
  • [4] Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial
    Xue Yang
    Zhiwei He
    Li Yuan
    Wenbin Huang
    Doudou Li
    Pingping Xiang
    Yu Chen
    Guofang Chen
    Chao Liu
    BMC Endocrine Disorders, 23
  • [5] Comparison of protective effects of teneligliptin and luseogliflozin on pancreatic β-cell function: randomized, parallel-group, multicenter, open-label study (SECRETE-I study)
    Shimoda, Masashi
    Katakura, Yukino
    Mashiko, Akiko
    Iwamoto, Masahiro
    Nakanishi, Shuhei
    Anno, Takatoshi
    Kawasaki, Fumiko
    Obata, Atsushi
    Fushimi, Yoshiro
    Sanada, Junpei
    Kohara, Kenji
    Isobe, Hayato
    Iwamoto, Yuichiro
    Hirukawa, Hidenori
    Tatsumi, Fuminori
    Kimura, Yukiko
    Kimura, Tomohiko
    Mune, Tomoatsu
    Kaku, Kohei
    Kaneto, Hideaki
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [6] Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial
    Son, Cheol
    Kasahara, Masato
    Tanaka, Tomohiro
    Satoh-Asahara, Noriko
    Kusakabe, Toru
    Nishimura, Kunihiro
    Miyamoto, Yoshihiro
    Kasama, Shu
    Hosoda, Kiminori
    DIABETES THERAPY, 2020, 11 (01) : 347 - 358
  • [7] Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial
    Cheol Son
    Masato Kasahara
    Tomohiro Tanaka
    Noriko Satoh-Asahara
    Toru Kusakabe
    Kunihiro Nishimura
    Yoshihiro Miyamoto
    Shu Kasama
    Kiminori Hosoda
    Diabetes Therapy, 2020, 11 : 347 - 358
  • [8] Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy
    Ainuddin, Jahan Ara
    Karim, Nasim
    Zaheer, Sidra
    Ali, Syed Sanwer
    Hasan, Anjum Ara
    JOURNAL OF DIABETES RESEARCH, 2015, 2015
  • [9] Multifactorial Intervention on Type 2 Diabetes (MIDiab) Study: A multicenter,open-label, randomized, parallel controlled, community trial
    Wang, Yupeng
    Guan, Qingbo
    Hou, Xu
    Zhang, Xu
    Zhang, Haiqing
    Xu, Chao
    Jing, Fei
    Ma, Shizhan
    Shao, Shanshan
    Zhao, Meng
    Guo, Qingling
    Zhong, Fang
    Gao, Ling
    Zhao, Jiajun
    JOURNAL OF DIABETES, 2020, 12 (11) : 862 - 864
  • [10] Efficacy of a Digital Diabetes Logbook for People With Type 1, Type 2, and Gestational Diabetes: Results From a Multicenter, Open-Label, Parallel-Group, Randomized Controlled Trial
    Ehrmann, Dominic
    Hermanns, Norbert
    Finke-Groene, Katharina
    Roos, Timm
    Kober, Johanna
    Schaefer, Vanessa
    Krichbaum, Michael
    Haak, Thomas
    Ziegler, Ralph
    Heinemann, Lutz
    Rieger, Cosima
    Bingol, Ezgi
    Kulzer, Bernhard
    Silbermann, Stephan
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024,
12345